Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC

奥西默替尼 危险系数 安慰剂 肿瘤科 肺癌 养生 无进展生存期 内科学 临床终点 医学 中期分析 放化疗 外科 置信区间 随机对照试验 化疗 表皮生长因子受体 病理 癌症 埃罗替尼 替代医学
作者
Shun Lu,Terufumi Kato,Xiaorong Dong,Myung‐Ju Ahn,Le-Van Quang,Nopadol Soparattanapaisarn,Takako Inoue,Chih-Liang Wang,Meijuan Huang,James Chih‐Hsin Yang,Manuel Cobo,Mustafa Özgüroğlu,Ignacio Casarini,Dang-Van Khiem,Virote Sriuranpong,Eduardo Henrique Cronemberger,Toshiaki Takahashi,Yotsawaj Runglodvatana,Ming Chen,Xiangning Huang
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:391 (7): 585-597 被引量:370
标识
DOI:10.1056/nejmoa2402614
摘要

Background Osimertinib is a recommended treatment for advanced non–small-cell lung cancer (NSCLC) with an epidermal growth factor receptor ( EGFR ) mutation and as adjuvant treatment for resected EGFR -mutated NSCLC. EGFR-tyrosine kinase inhibitors have shown preliminary efficacy in unresectable stage III EGFR -mutated NSCLC. Methods In this phase 3, double-blind, placebo-controlled trial, we randomly assigned patients with unresectable EGFR -mutated stage III NSCLC without progression during or after chemoradiotherapy to receive osimertinib or placebo until disease progression occurred (as assessed by blinded independent central review) or the regimen was discontinued. The primary end point was progression-free survival as assessed by blinded independent central review. Results A total of 216 patients who had undergone chemoradiotherapy were randomly assigned to receive osimertinib (143 patients) or placebo (73 patients). Osimertinib resulted in a significant progression-free survival benefit as compared with placebo: the median progression-free survival was 39.1 months with osimertinib versus 5.6 months with placebo, with a hazard ratio for disease progression or death of 0.16 (95% confidence interval [CI], 0.10 to 0.24; P<0.001). The percentage of patients who were alive and progression free at 12 months was 74% (95% CI, 65 to 80) with osimertinib and 22% (95% CI, 13 to 32) with placebo. Interim overall survival data (maturity, 20%) showed 36-month overall survival among 84% of patients with osimertinib (95% CI, 75 to 89) and 74% with placebo (95% CI, 57 to 85), with a hazard ratio for death of 0.81 (95% CI, 0.42 to 1.56; P=0.53). The incidence of adverse events of grade 3 or higher was 35% in the osimertinib group and 12% in the placebo group; radiation pneumonitis (majority grade, 1 to 2) was reported in 48% and 38%, respectively. No new safety concerns emerged. Conclusions Treatment with osimertinib resulted in significantly longer progression-free survival than placebo in patients with unresectable stage III EGFR -mutated NSCLC. (Funded by AstraZeneca; LAURA ClinicalTrials.gov number, NCT03521154 .)
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
gpccyq发布了新的文献求助10
1秒前
伶俐的灵珊完成签到,获得积分10
1秒前
1秒前
1秒前
大时钟的应助被Wissenheimer采纳,获得10
1秒前
要减肥鸣凤完成签到,获得积分10
1秒前
万能图书馆的应助被又又采纳,获得10
1秒前
阿杰完成签到,获得积分10
2秒前
2秒前
汉堡包的应助被GAO采纳,获得10
2秒前
3秒前
zihaoW发布了新的文献求助30
3秒前
3秒前
3秒前
u亩完成签到 ,获得积分10
3秒前
4秒前
赵123发布了新的文献求助10
4秒前
丘比特的应助被gxgxnn采纳,获得10
5秒前
房东的猫发布了新的文献求助10
5秒前
房东的猫发布了新的文献求助10
5秒前
5秒前
脑洞疼的应助被jias采纳,获得10
5秒前
5秒前
5秒前
顺利的访琴完成签到,获得积分10
6秒前
wanci的应助被caiwenwen采纳,获得10
7秒前
约翰完成签到,获得积分10
7秒前
桃小包完成签到,获得积分10
7秒前
房东的猫发布了新的文献求助10
8秒前
8秒前
10秒前
10秒前
10秒前
sophia完成签到,获得积分10
10秒前
丘比特的应助被包容的小蚂蚁采纳,获得10
11秒前
哇哈哈哈完成签到,获得积分10
11秒前
Ava的应助被juphen2采纳,获得10
12秒前
稳重的烙完成签到 ,获得积分10
12秒前
天真彩虹完成签到,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182102
求助须知:如何正确求助?哪些是违规求助? 9571775
关于积分的说明 21819723
捐赠科研通 7778500
什么是DOI,文献DOI怎么找? 3433617
关于科研通互助平台的介绍 2557786
邀请新用户注册赠送积分活动 2479651